Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

650 - HGCSG1503 : A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer : Analysis of GERCOR index.


24 Nov 2018


Poster display - Cocktail


Tumour Site

Colon and Rectal Cancer


Kazuhiro Suzuki


Annals of Oncology (2018) 29 (suppl_9): ix28-ix45. 10.1093/annonc/mdy431


K. Suzuki1, S. Yuki2, S. Nakano2, Y. Kawamoto2, H. Nakatsumi3, K. Hatanaka4, T. Ando5, K. Furukawa6, A. Ishiguro7, T. Ohta8, K. Eto9, J. Nakajima10, M. Nakamura11, S. Sogabe12, K. Kato13, M. Tateyama14, S. Kato15, M. Sekiguchi16, Y. Sakata17, Y. Komatsu3

Author affiliations

  • 1 Internal Medicine, Misawa City Hospital, 033-0022 - Misawa/JP
  • 2 Gastroenterology And Hepatology, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 3 Cancer Center, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 4 Gastroenterology, Hakodate Municipal Hospital, 041-8680 - Hakodate/JP
  • 5 Gastroenterology And Hematology, Faculty of medicine, University of Toyama, 930-0194 - Toyama/JP
  • 6 Gastroenterology, Niigata City General Hospital, Niigata/JP
  • 7 Medical Oncology, Teine Keijinkai Hospital, 006-8555 - Sapporo/JP
  • 8 Gastroenterology, Sapporo Higashi Tokushukai Hospital, Sapporo/JP
  • 9 Gastroenterology, Tomakomai City Hospital, Tomakomai/JP
  • 10 Gastroenterology, Obihiro Kosei Hospital, Obihiro/JP
  • 11 Gastroenterology, Sapporo City General Hospital, 060-8604 - Sapporo/JP
  • 12 Medical Oncology, KKR Sapporo Medical Center, Sapporo/JP
  • 13 Gastroenterology, Iwamizawa Municipal General Hospital, Iwamizawa/JP
  • 14 Internal Medicine, Tomakomai Nisshou Hospital, Tomakomai/JP
  • 15 Gastroenterology, Sapporo Hokuyu Hospital, Sapporo/JP
  • 16 Data Center, Hokkaido Gastrointestinal Cancer Study Group, Sapporo/JP
  • 17 Ceo, Misawa City Hospital, 033-0022 - Misawa/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 650


In the treatment for metastatic colorectal cancer (mCRC), it is essential for understanding the prognosis of each individual patient. GERCOR index (GI) based on performance status and serum LDH has been previously proposed. However, in the later line setting, the validity of GI has not been reported in patients treated by TAS-102.


411 patients with mCRC treated by TAS-102 were retrospectively registered from 28 centers in Japan. Selection criteria for this analysis were: (1) ECOG performance status 0-2, (2) presence of serum LDH before the start of TAS-102, and (3) presence of KRAS mutational status. Univariate and multivariate analysis for overall survival (OS) and progression-free survival (PFS) were performed using patient characteristics. Survival analyses were performed with Kaplan-Meier method, log-rank test and Cox proportional hazards model.


In 389 patients, all data were available for prognostic categorization. Median OS and PFS were 7.4 and 2.2 months in this analysis set. The distribution of GI were Low risk (L: n = 64), Intermediate risk (I: n = 158), and High risk (H: n = 167). The median OS of L, I, and H were 13.5, 8.4, and 5.3 months, respectively. For OS, there were significant difference between L and H (p < 0.001), I and H (p < 0.001), and L and I (p = 0.003). The median PFS of L, I, and H were 2.8, 2.6, and 1.9 months, respectively. For PFS, there were significant difference between L and H (p < 0.001), I and H (p = 0.015), and L and I (p = 0.007). In Cox multivariate analysis, GI showed an independent prognostic (L vs I; HR 1.566, p = 0.008 / L vs H; HR 2.476, p < 0.001) and predictive impact (L vs I; HR 1.427, p = 0.022 / L vs H; HR 1.932, p < 0.001).


In this analysis, GI might be a predictive and prognostic factor in later line treatment with TAS-102 for patients with mCRC. The prospective evaluation is needed for the further validation.

Editorial acknowledgement

Clinical trial identification

UMIN000020551, 2016/02/02.

Legal entity responsible for the study

Non-profit Organization: Hokkaido Gastrointestinal Cancer Study Group.


Non-profit Organization: Hokkaido Gastrointestinal Cancer Study Group.


S. Yuki: Honoraria: Taiho Pharmaceutical Co., Ltd. Y. Komatsu: Honoraria, donation, research fund: Taiho Pharmaceutical. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.